Search
somapacitan-beco (Sogroya)
Indications:
- treatment of adults with growth hormone deficiency
Contraindications:
- severe or proliferative diabetic retinopathy
- malignancy
- critical illness
Dosage:
- start 1.5 mg SQ weekly into thigh or abdomen (rotate injection sites)
- increase dose 0.5-1.5 mg every 2-4 weeks until desired dose reached
- titrate to clinical effect & serum IGF-1
- maximum 8 mg weekly
Injection: 10 mg/1.5 mL (6.7 mg/mL)b. single patient use prefilled pen
Adverse effects:
- lipohypertrophy/lipoatrophy at injection site (rotate injection site regularly)
- increased risk of neoplasm
- hyperglycemia, diabetes mellitus & complications of diabetes mellitus
- intracranial hypertension (usually within 8 weeks of initiation)
- hypersensitivity
- fluid retention (edema)
- hypoadrenalism
- hypothyroidism
- pancreatitis
- back pain, arthralgia, dyspepsia, sleep disorder, dizziness, tonsillitis, peripheral edema, vomiting, adrenal insufficiency, hypertension, weight increase, anemia
- increased serum creatine phosphokinase
Laboratory:
- monitor serum IGF-1
- serum glucose
- serum cortisol
- serum TSH
Mechanism of action:
- human growth hormone analog
General
Growth Hormone
recombinant protein; chimer
metabolic agent (metabolic modifier)
References
- Highlights of Prescribing Information
somapacitan-beco (Sogroya)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761156s000lbl.pdf
- Wikipedia: Somapacitan
https://en.wikipedia.org/wiki/Somapacitan
- Johannsson G, Gordon MB, Hojby Rasmussen M
Once-weekly Somapacitan is Effective and Well Tolerated in Adults
with GH Deficiency: A Randomized Phase 3 Trial.
J Clin Endocrinol Metab. 2020 Apr 1;105(4):e1358-76.
PMID: 32022863 PMCID: PMC7076631 Free PMC article